Skip to main content

Table 1 (abstract P047). Kaplan-Meier estimates, % (95% CI), for use of selected medications and attainment of inactive or minimally active disease within 70 weeks of JIA diagnosis

From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)

Group

Cohort

DMARD

Biologic

Prednisone

Joint Injection

Inactive Wallace

Inactive 1 cJADAS10

Minimal 2 cJADAS10

All categories

2005-10

43 (40,47)

6 (5,7)

16 (14,18)

43 (40,46)

63 (60,66)

50 (47,53)

69 (66,72)

2017-21

60 (56,64)

26 (23,30)

16 (13,19)

36 (32,40)

84 (80, 87)

69 (65,73)

84 (81,87)

Oligoarthritis

2005-10

21 (18,26)

2 (1,4)

5 (3,7)

56 (51,61)

78 (74,82)

56 (51,61)

75 (71,79)

2017-21

46 (39,52)

10 (6,15)

6 (3,10)

55 (49,62)

90 (85,93)

73 (67,79)

89 (85,93)

Polyarthritis RF negative

2005-10

78 (72,84)

6 (4,10)

18 (13,24)

38 (32,45)

53 (47,60)

46 (39,56)

64 (58,71)

2017-21

84 (76,90)

41 (32,52)

22 (16,31)

29 (21,39)

86 (78,92)

80 (72,87)

88 (81,93)

Systemic

2005-10

63 (51,75)

18 (10,30)

77 (66,87)

8 (3,18)

68 (56,79)

62 (50,74)

80 (69,89)

2017-21

47 (29,69)

66 (49,83)

83 (65,95)

--

91 (76,98)

78 (59,92)

85 (67,96)

  1. 1cJADAS scores of ≤1.1 and ≤ 2.5, 2≤ 4 and ≤ 5, for subjects with oligo- and polyarthritis, respectively